Madhuri Koti, Queen's University

Research

Bladder Cancer Innovative Targets,Pre-Clinical Studies Translational Research Tumor Microenvironment Biomarker Chemotherapy Immunotherapy

Latest papers

Editorial Comment.
The Journal of urology · 2026 · senior author
The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer.
International journal of radiation oncology, biology, physics · 2026
Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Cancer research · 2025

All 69 publications

Latest funding

Targeting B cell exhaustion in BCG non-responsive bladder cancer
CIHR · 2024 · Nominated PI
$975,376
Unique extracellular vesicle signatures in the pathophysiology of endometriosis
CIHR · 2023 · Co-investigator
$150,000
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting
CIHR · 2023 · Co-investigator
$914,176

All 11 grants and awards

69 publications.

01

Editorial Comment.

Sachdeva K, Koti M

The Journal of urology2026Senior author

DOI: 10.1097/ju.0000000000004841 PMID: 41294041

02

The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer.

Hassan N, Michaud E, Mansure JJ, Farag M, Kool R, Alessa M, Sadri E, Cury F, Brimo F, Koti M, Kassouf W

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.09.056 PMID: 41135713

03

Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Laight BJ, Harper D, Dmytryk N, Zhang CS, Shi C, Garven A, Nauman RW, Kment J, Alotaibi F, Shapovalov I, Hoskin V, Gao Y, Mewburn J, Vlasschaert C, Wang A, Simonetti J, LeBrun D, Tyryshkin K, Berman DM, Simpson AL, Graham CH, Craig AW, Basta S, Koti M, Greer PA

Cancer research2025

DOI: 10.1158/0008-5472.can-24-3686 PMID: 40299778

04

Nonmodifiable Drivers of Response to Bacillus Calmette-Guérin: Considerations of Age, Sex, and Chronic Inflammation for the Management of Nonmuscle-Invasive Bladder Cancer.

Koti M, Michaud E, Siemens DR

The Journal of urology2025First author

DOI: 10.1097/ju.0000000000004632 PMID: 40493428

05

Endocannabinoids and their receptors modulate endometriosis pathogenesis and immune response.

Lingegowda H, Zutautas KB, Wei Y, Yolmo P, Sisnett DJ, McCallion A, Koti M, Tayade C

eLife2024

DOI: 10.7554/elife.96523 PMID: 39120997

06

Tertiary lymphoid structures in endometriosis.

Zutautas KB, Yolmo P, Xu M, Childs T, Koti M, Tayade C

F&S science2024

DOI: 10.1016/j.xfss.2024.10.001 PMID: 39370108

07

Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non-Muscle Invasive Bladder Cancer.

Yolmo P, Rahimi S, Chenard S, Conseil G, Jenkins D, Sachdeva K, Emon I, Hamilton J, Xu M, Rangachari M, Michaud E, Mansure JJ, Kassouf W, Berman DM, Siemens DR, Koti M

Cancer immunology research2024Senior author

DOI: 10.1158/2326-6066.cir-23-1114 PMID: 38916567

08

Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.

Yolmo P, Siemens DR, Koti M

European urology2024Senior author

DOI: 10.1016/j.eururo.2023.12.003 PMID: 38143216

09

A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.

Koti M, Robert Siemens D

European urology2023First author

DOI: 10.1016/j.eururo.2023.06.017 PMID: 37400353

10

The Evolving Landscape of Bladder Tertiary Lymphoid Structures.

Koti M, Siemens DR

The Journal of urology2023First author

DOI: 10.1097/ju.0000000000003530 PMID: 37161260

Targeting B cell exhaustion in BCG non-responsive bladder cancer

Nominated PICIHR2024Project Grant

Principal investigators: Koti, Madhuri

Keywords: Bladder Cancer; Innovative Targets,; Pre-Clinical Studies; Translational Research; Tumor Microenvironment

$975,376

Unique extracellular vesicle signatures in the pathophysiology of endometriosis

Co-investigatorCIHR2023Catalyst Grant: NWHRI: Innovation Fund - Biomedical Discovery Grants

Principal investigators: Tayade, Chandrakant

Keywords: Disease Stages; Endometriosis; Extracellular Vesicles; Multiomics Approach; Pain; Vascularization

$150,000

Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting

Co-investigatorCIHR2023Project Grant

Principal investigators: Tayade, Chandrakant

Keywords: Endometriosis; Fibrosis; Inflammation; Innate Lymphoid Cells 2; Interleukin-33; Therapeutic Development; Vascularization

$914,176

Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting.

Co-investigatorCIHR2022Project Grant

Principal investigators: Tayade, Chandrakant

Keywords: Endometriosis; Fibrosis; Inflammation; Innate Lymphoid Cells 2; Interleukin-33; Therapeutic Development; Vascularization

$100,000

Role of trained immunity in the response to BCG immunotherapy of bladder cancer

Co-investigatorCIHR2020Project Grant

Principal investigators: Graham, Charles H; Siemens, Robert

Keywords: Adaptive Immunity; Bladder Cancer; Immunotherapy; Innate Immunity

$1,086,300

Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality.

Co-investigatorCIHR2020Project Grant

Principal investigators: Tayade, Chandrakant

Keywords: Angiogenesis; Cannabinoids; Endometriosis; Inflammation; Pain; Therapuetics

$868,275

Exploiting tumour innate immunity for sensitization of ovarian tumours to PD-L1 immune checkpoint blockade immunotherapy

Nominated PICIHR2018Project Grant

Principal investigators: Koti, Madhuri

Keywords: Biomarker; Chemotherapy; Immunotherapy; Interferon; Ovarian Cancer

$765,000

Acquisition of malignant phenotypes in tumour cells mediated by the PD-1/PD-L1 immune checkpoint

Co-investigatorCIHR2016Project Grant

Principal investigators: Graham, Charles H

Keywords: Cancer; Drug Resistance; Immune Checkpoint; Metastasis

$443,410

Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis

Co-investigatorCIHR2016Project Grant

Principal investigators: Tayade, Chandrakant

Keywords: Cytokines/Chemokines; Diagnostic Markers; Endometriosis; Immune Dysfunction; Infertility; Inflamamtion; Therapeutic Target

$619,650

Live Cell Imaging Platform for Dynamic Studies of Cellular Interactions

Co-investigatorNSERC2016Research Tools and Instruments

Principal investigators: Zhang, Shetuan

$141,951

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Biomedical and Molecular Sciences
Surgery
Obstetrics and Gynecology
Cancer Care and Epidemiology
Medicine
Pathology and Molecular Medicine
Pathology and Laboratory Medicine
Other

1 shared papers, latest 2020

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Bladder Cancer Dear Professor Koti, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Editorial Comment." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Targeting B cell exhaustion in BCG non-responsive bladder cancer" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Madhuri Koti

Research

Latest papers

Latest funding

Editorial Comment.

The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer.

Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Nonmodifiable Drivers of Response to Bacillus Calmette-Gu&#xe9;rin: Considerations of Age, Sex, and Chronic Inflammation for the Management of Nonmuscle-Invasive Bladder Cancer.

Endocannabinoids and their receptors modulate endometriosis pathogenesis and immune response.

Tertiary lymphoid structures in endometriosis.

Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Gu&#xe9;rin in Non-Muscle Invasive Bladder Cancer.

Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.

A Step Closer to Predicting Progression After Bacillus Calmette-Gu&#xe9;rin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.

The Evolving Landscape of Bladder Tertiary Lymphoid Structures.

Live Cell Imaging Platform for Dynamic Studies of Cellular Interactions

Frequent collaborators

Chandrakant Tayade

Kathrin Tyryshkin

Wassim Kassouf

Tiziana Cotechini

Andrew Robinson

Paul Toren

David Berman

Olga Bougie

Sarah Ferguson

Melanie Jaeger

Charles Graham

Sameh Basta

Parvin Mousavi

David Lebrun

Anne-Marie Mes-Masson

Dirk Lange

Manu Rangachari

Lee-Hwa Tai

James Petrik

Vincent Fradet

Nonmodifiable Drivers of Response to Bacillus Calmette-Guérin: Considerations of Age, Sex, and Chronic Inflammation for the Management of Nonmuscle-Invasive Bladder Cancer.

Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non-Muscle Invasive Bladder Cancer.

A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.